Show simple item record

dc.contributor.authorTariq, Noor-Ul-Ain
dc.contributor.authorVogel, A
dc.contributor.authorMcNamara, Mairéad G
dc.contributor.authorValle, Juan W
dc.date.accessioned2018-06-30T14:06:53Z
dc.date.available2018-06-30T14:06:53Z
dc.date.issued2018
dc.identifier.citationBiliary tract cancer: implicated immune-mediated pathways and their associated potential targets. 2018, 41(5): 298-304 Oncol Res Treaten
dc.identifier.issn2296-5262
dc.identifier.pmid29705791
dc.identifier.doi10.1159/000488997
dc.identifier.urihttp://hdl.handle.net/10541/621077
dc.description.abstractThere is a well-established link between biliary tract cancers (BTC) and chronic inflammatory conditions such as primary sclerosing cholangitis, chronic cholecystitis, chronic cholelithiasis, liver fluke-associated infestations, and chronic viral hepatic infections. These associated risk factors highlight the potential for development of immune-modulatory agents in this poor-prognostic disease group with limited treatment options. Clinical trials have evaluated the role of immune cells, inflammatory biomarkers, vaccines, cytokines, adoptive cell therapy, and immune checkpoint inhibitors in patients with BTC. Although these have demonstrated the importance of the immune environment in BTC, currently none of the immune-based therapies have been approved for use in this disease group. The role of immunomodulatory agents is a developing field and has yet to find its way 'from bench to bedside' in BTC.
dc.language.isoenen
dc.rightsArchived with thanks to Oncology research and treatmenten
dc.titleBiliary tract cancer: implicated immune-mediated pathways and their associated potential targets.en
dc.typeArticleen
dc.contributor.departmentThe Christie Hospital NHS Trust, Manchesteren
dc.identifier.journalOncology Research and Treatmenten
refterms.dateFOA2018-12-06T09:23:00Z
html.description.abstractThere is a well-established link between biliary tract cancers (BTC) and chronic inflammatory conditions such as primary sclerosing cholangitis, chronic cholecystitis, chronic cholelithiasis, liver fluke-associated infestations, and chronic viral hepatic infections. These associated risk factors highlight the potential for development of immune-modulatory agents in this poor-prognostic disease group with limited treatment options. Clinical trials have evaluated the role of immune cells, inflammatory biomarkers, vaccines, cytokines, adoptive cell therapy, and immune checkpoint inhibitors in patients with BTC. Although these have demonstrated the importance of the immune environment in BTC, currently none of the immune-based therapies have been approved for use in this disease group. The role of immunomodulatory agents is a developing field and has yet to find its way 'from bench to bedside' in BTC.


Files in this item

Thumbnail
Name:
Submitted 4 April Biliary tract ...
Size:
88.00Kb
Format:
Microsoft Word 2007
Description:
author manuscript

This item appears in the following Collection(s)

Show simple item record